Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
Phase 3
Completed
NCT05553366
| Condition | Acute Pain |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Vertex Pharmaceuticals Incorporated |
|---|
| Status | Completed |
|---|
| Enrollment | 1,075 participants |
|---|
| Interventions | SUZ, HB/APAP, Placebo (matched to SUZ), Placebo (matched to HB/APAP) |
|---|
| Start date | Oct 3, 2022 |
|---|
| Completion date | Dec 15, 2023 |
|---|
| Results posted | Aug 1, 2025 |
|---|
Summary
The purpose of this study is to evaluate the efficacy and safety of suzetrigine for acute pain after a bunionectomy.
Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to Placebo
0 to 48 hours After First Dose of Study Drug · units on a scale
| Placebo | 70.6 ± 6.3 units on a scale |
|---|
| Suzetrigine (SUZ) | 99.9 ± 4.5 units on a scale |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.